Ryzneuta (Efbemalenograstim alfa)
- Medicine Name: Ryzneuta
- API: Efbemalenograstim alfa
- Dosage Form & Strength: Injection: 20 mg/mL solution in a single-dose prefilled syringe
- Manufactured By: Evive Biotechnology
Ryzneuta (efbemalenograstim alfa) is a leukocyte growth factor used for reducing the incidence of infection, as manifested by febrile neutropenia (FN), in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer medicines associated with a clinically significant incidence of febrile neutropenia (FN).
Recommended Dosage: The recommended dosage of Ryzneuta is a single subcutaneous (SC) injection of 20 mg administered once per chemotherapy cycle at least 24 hours after cytotoxic chemotherapy. Do not administer this therapeutic drug within 14 days before and <24 hours after administration of cytotoxic chemotherapy.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.